A Novel Urinary miRNA Biomarker for Early Detection of Colorectal Cancer.
A Novel Urinary miRNA Biomarker for Early Detection of Colorectal Cancer.
复制标题
DOI：
10.3390/cancers14020461
复制
发表时间：
2022-01-17
期刊：
影响因子：
5.2
通讯作者：
Kataoka H
中科院分区：
文献类型：
--
作者：
Iwasaki H;Shimura T;Kitagawa M;Yamada T;Nishigaki R;Fukusada S;Okuda Y;Katano T;Horike SI;Kataoka H
早期诊断对于结直肠癌（CRC）的挽救生命至关重要。由于结肠镜检查的侵入性和高成本，不适合作为结直肠癌的筛查方法，因此，可靠的、非侵入性的诊断标志物有望用于结直肠癌的诊断。在这项病例对照研究中，我们建立了一种完全非侵入性的新型尿microRNA（miRNA）生物标志物组合，用于诊断CRC。在包括415名参与者的独立年龄和性别匹配的三个队列中，与健康对照组相比，CRC组中这些miRNA的尿液水平一直升高。值得注意的是，组合miR-129-1- 3 p和miR-566的组显示0/I期CRC的AUC为0.845，其可以用内窥镜切除术治疗。由于非侵入性生物标志物作为侵入性结肠镜检查的替代来检测结直肠癌（CRC）是期望的，我们进行了这项研究以确定由microRNA（miRNAs）组成的尿液生物标志物。总共有415名年龄和性别匹配的参与者，包括206名CRC患者和209名健康对照（HC），被随机分为三组：（1）发现队列（CRC，n = 3; HC，n = 6）;（2）训练队列（140对）;和（3）验证队列（63对）。在两组之间异常表达的11种尿miRNAs中，miR-129-1- 3 p和miR-566是检测CRC的显著独立的生物标志物。由两种miRNA组成的小组可以区分训练队列中的CRC患者和HC参与者，曲线下面积（AUC）= 0.811。该组在验证队列中显示出良好的疗效，AUC = 0.868。这种结合miR-129-1- 3 p和miR-566的尿生物标志物甚至可以有效地检测0/I期CRC，AUC = 0.845。此外，miR-129-1- 3 p和miR-566在原发性肿瘤组织中的表达水平显著高于邻近正常组织。我们建立的由尿miR-129-1- 3 p和miR-566组成的新生物标志物能够实现CRC的非侵入性和早期检测。
Early diagnosis is critically important to achieve life-saving therapy for colorectal cancer (CRC). Since colonoscopy is not suitable as a screening method for CRC due to its invasiveness and high-cost, reliable and non-invasive diagnostic biomarkers are hopeful for CRC. In this case-control study, we established completely non-invasive, novel urinary microRNA (miRNA) biomarker panel combining miR-129-1-3p and miR-566 for the diagnosis of CRC. In the independent age- and sex-matched three cohorts comprising 415 participants, urinary levels of these miRNAs were consistently elevated in the CRC group compared to the healthy controls. Notably, the panel of combining miR-129-1-3p and miR-566 revealed an AUC of 0.845 for stage 0/I CRC that can be treated with endoscopic resection. Since noninvasive biomarkers as an alternative to invasive colonoscopy to detect colorectal cancer (CRC) are desired, we conducted this study to determine the urinary biomarker consisting of microRNAs (miRNAs). In total, 415 age- and sex-matched participants, including 206 patients with CRC and 209 healthy controls (HCs), were randomly divided into three groups: (1) the discovery cohort (CRC, n = 3; HC, n = 6); (2) the training cohort (140 pairs); and (3) the validation cohort (63 pairs). Among 11 urinary miRNAs with aberrant expressions between the two groups, miR-129-1-3p and miR-566 were significantly independent biomarkers that detect CRC. The panel consisting of two miRNAs could distinguish patients with CRC from HC participants with an area under the curve (AUC) = 0.811 in the training cohort. This panel showed good efficacy with an AUC = 0.868 in the validation cohort. This urinary biomarker combining miR-129-1-3p and miR-566 could detect even stage 0/I CRC effectively with an AUC = 0.845. Moreover, the expression levels of both miR-129-1-3p and miR-566 were significantly higher in primary tumor tissues than in adjacent normal tissue. Our established novel biomarker consisting of urinary miR-129-1-3p and miR-566 enables noninvasive and early detection of CRC.
登录
查看更多内容
影响因子：
8
作者：
Di Ruocco F;Basso V;Rivoire M;Mehlen P;Ambati J;De Falco S;Tarallo V
通讯作者：
Tarallo V
影响因子：
3.7
作者：
Drusco A;Nuovo GJ;Zanesi N;Di Leva G;Pichiorri F;Volinia S;Fernandez C;Antenucci A;Costinean S;Bottoni A;Rosito IA;Liu CG;Burch A;Acunzo M;Pekarsky Y;Alder H;Ciardi A;Croce CM
通讯作者：
Croce CM
影响因子：
39
作者：
Bretthauer M;Kaminski MF;Løberg M;Zauber AG;Regula J;Kuipers EJ;Hernán MA;McFadden E;Sunde A;Kalager M;Dekker E;Lansdorp-Vogelaar I;Garborg K;Rupinski M;Spaander MC;Bugajski M;Høie O;Stefansson T;Hoff G;Adami HO;Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group
通讯作者：
Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group
影响因子：
4.1
作者：
Armstrong, David A.;Dessaint, John A.;Ashare, Alix
通讯作者：
Ashare, Alix
影响因子：
28.4
作者：
Global Burden of Disease Cancer Collaboration;Fitzmaurice C;Allen C;Barber RM;Barregard L;Bhutta ZA;Brenner H;Dicker DJ;Chimed-Orchir O;Dandona R;Dandona L;Fleming T;Forouzanfar MH;Hancock J;Hay RJ;Hunter-Merrill R;Huynh C;Hosgood HD;Johnson CO;Jonas JB;Khubchandani J;Kumar GA;Kutz M;Lan Q;Larson HJ;Liang X;Lim SS;Lopez AD;MacIntyre MF;Marczak L;Marquez N;Mokdad AH;Pinho C;Pourmalek F;Salomon JA;Sanabria JR;Sandar L;Sartorius B;Schwartz SM;Shackelford KA;Shibuya K;Stanaway J;Steiner C;Sun J;Takahashi K;Vollset SE;Vos T;Wagner JA;Wang H;Westerman R;Zeeb H;Zoeckler L;Abd-Allah F;Ahmed MB;Alabed S;Alam NK;Aldhahri SF;Alem G;Alemayohu MA;Ali R;Al-Raddadi R;Amare A;Amoako Y;Artaman A;Asayesh H;Atnafu N;Awasthi A;Saleem HB;Barac A;Bedi N;Bensenor I;Berhane A;Bernabé E;Betsu B;Binagwaho A;Boneya D;Campos-Nonato I;Castañeda-Orjuela C;Catalá-López F;Chiang P;Chibueze C;Chitheer A;Choi JY;Cowie B;Damtew S;das Neves J;Dey S;Dharmaratne S;Dhillon P;Ding E;Driscoll T;Ekwueme D;Endries AY;Farvid M;Farzadfar F;Fernandes J;Fischer F;G/Hiwot TT;Gebru A;Gopalani S;Hailu A;Horino M;Horita N;Husseini A;Huybrechts I;Inoue M;Islami F;Jakovljevic M;James S;Javanbakht M;Jee SH;Kasaeian A;Kedir MS;Khader YS;Khang YH;Kim D;Leigh J;Linn S;Lunevicius R;El Razek HMA;Malekzadeh R;Malta DC;Marcenes W;Markos D;Melaku YA;Meles KG;Mendoza W;Mengiste DT;Meretoja TJ;Miller TR;Mohammad KA;Mohammadi A;Mohammed S;Moradi-Lakeh M;Nagel G;Nand D;Le Nguyen Q;Nolte S;Ogbo FA;Oladimeji KE;Oren E;Pa M;Park EK;Pereira DM;Plass D;Qorbani M;Radfar A;Rafay A;Rahman M;Rana SM;Søreide K;Satpathy M;Sawhney M;Sepanlou SG;Shaikh MA;She J;Shiue I;Shore HR;Shrime MG;So S;Soneji S;Stathopoulou V;Stroumpoulis K;Sufiyan MB;Sykes BL;Tabarés-Seisdedos R;Tadese F;Tedla BA;Tessema GA;Thakur JS;Tran BX;Ukwaja KN;Uzochukwu BSC;Vlassov VV;Weiderpass E;Wubshet Terefe M;Yebyo HG;Yimam HH;Yonemoto N;Younis MZ;Yu C;Zaidi Z;Zaki MES;Zenebe ZM;Murray CJL;Naghavi M
通讯作者：
Naghavi M